Navigation Links
WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
Date:6/21/2009

SHANGHAI, June 21 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Wei-Min Chang has been appointed Vice President of Operations and General Manager of the company's SynTheAll (STA) manufacturing facility, located in the Jinshan chemical industry zone of Shanghai. Mr. Chang will report to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Eric Gu, former Vice President of Operations and General Manager of STA, has been appointed Vice President of Business Development for Manufacturing Services, reporting to Dr. Suhan Tang, Chief Manufacturing Officer.

The Company's SynTheAll facility manufactures active pharmaceutical ingredients (APIs) and advanced intermediates for our customers' use in preclinical and clinical trials. The company recently completed construction of an expanded facility, known as SynTheAll Phase 2, to produce advanced intermediates and APIs for late-stage clinical trials and commercial supplies. This new facility is expected to open in stages, beginning in late 2009.

Prior to joining WuXi, Mr. Chang worked at Eastbound Synopharma (HK) Holding Co. as Vice President of Chemical Development, responsible for research and development, small-scale manufacturing, quality control/quality assurance, regulatory affairs and other general administrative functions at Eastbound Shanghai Institute. From 1999 to 2006, he worked for Taiwan Biotech as the company's head of U.S. operations and as Vice President of R&D/Quality/Regulatory Affairs/API Operations. From 1989 to 1998, he was Senior Process Engineer/Chemical Engineer at Eli Lilly, where he was responsible for designing and developing manufacturing processes for advanced intermediates, APIs, and bulk pharmaceuticals at both laboratory and pilot- plant scale. Earlier, he was Chief Engineer/Chemist and Environmental, Health and Safety Director at Frismar, Inc.

"We are delighted to have someone with Mr. Chang's extensive manufacturing experience to manage our Jinshan facility," said Dr. Li. "Wei-Min's knowledge of cGMP manufacturing operations within the pharmaceutical, biotechnology, and chemical industries will help WuXi manage its manufacturing facilities efficiently and effectively. I also want to thank Eric Gu for his service as the previous general manager of the facility and to congratulate him on his appointment to manage business development for our Manufacturing Services."

Mr. Chang received a bachelor's degree in Chemistry from Tamkang University in Taiwan, a Master's degree in Chemical Engineering from the University of Connecticut, and an MBA from Indiana Wesleyan University.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
2. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
3. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
4. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
5. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
6. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
7. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
8. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
9. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
10. Pharmatech 2.0: Introducing Pharmatech Oncology
11. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... British Virgin Islands (PRWEB) , ... April 27, ... ... Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton ... he was an Executive Director and one of the founding commercial leaders responsible ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group ... Ross is the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, ... hematopoietic stem cell transplantation for hematologic disorders and the suppression of graft vs. host ...
(Date:4/26/2016)... ... April 27, 2016 , ... ... Rothgerber Christie LLP as an associate in the firm’s Intellectual Property practice group. ... mechanical and electromechanical patent applications. He has an electrical engineering and computer engineering ...
(Date:4/26/2016)... ... ... Mr. Palmer created the RPO business for Ceridian and lead the Public ... contract in the U.S. intelligence community with The SI (a Lockheed Martin divestiture). , ... of Accolo. “We are growing and his experience guiding our expansion is unparalleled. ...
Breaking Biology Technology:
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/8/2016)... N.C. , March 8, 2016   ... sensor technology, today announced it has secured $11M ... by GII Tech, a new venture fund being ... with additional participation from existing investors TDF Ventures ... the funds to continue its triple-digit growth and ...
(Date:3/3/2016)... SOTO, Kansas , March 3, 2016 ... Oncimmune,s Early CDT®-Lung, a blood test to aid ... cancer Early CDT®-Lung test to its clients ... Early CDT®-Lung test to its clients which include ... a leader in early cancer detection, today announced a ...
Breaking Biology News(10 mins):